Identification of favorable subgroups for alternative anti-androgen therapy in castration-resistant prostate cancer.

Suzuki, Kotaro; Terakawa, Tomoaki; Shigemura, Katsumi; Furukawa, Junya; Harada, Kenichi; Hinata, Nobuyuki; Nakano, Yuzo; Fujisawa, Masato

Suzuki, Kotaro; Terakawa, Tomoaki; Shigemura, Katsumi; Furukawa, Junya; Harada, Kenichi; Hinata, Nobuyuki; Nakano, Yuzo; Fujisawa, Masato.

Afiliação

Suzuki K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Terakawa T; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Shigemura K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Furukawa J; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Harada K; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Hinata N; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Nakano Y; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.
Fujisawa M; Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650-0017, Japan.

Mol Clin Oncol ; 11(5): 523-530, 2019 Nov.

Article em En | MEDLINE | ID: mdl-31620284

Palavras-chave

alternative anti-androgen therapy; castration-resistant prostate cancer; flutamide; prostate-specific antigen progression-free survival; prostate-specific antigen response; secondary hormonal therapy

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Idioma: En Revista: Mol Clin Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google